ArticleBMJ open gastroenterology2026
Burden of non-cancer comorbidities and mortality in chronic pancreatitis: a retrospective cohort study.
Article in BMJ open gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveChronic pancreatitis (CP) is a progressive fibro-inflammatory disease associated with increased comorbidity and mortality. This study aimed to characterise the natural history of CP by assessing comorbidity prevalence and mortality in a CP cohort.
methodsA retrospective cohort study was performed at Nottingham University Hospitals NHS Trust, including patients diagnosed with CP between 1 January 2006 and 31 December 2014. Participants were followed up until 31 May 2023. Comorbidity prevalence was compared with national data from England in 2022 to calculate standardised prevalence ratios (SPRs). Similarly, standardised mortality ratios (SMRs) were also evaluated.
resultsOf the 1003 patients with CP, 678 who resided within the Greater Nottingham area were included in the study cohort. The overall median follow-up was 5.7 years (IQR 1.2-10.6). Compared with the general population, patients with CP had significantly elevated SPRs for heart failure (3.0; 95% CI 2.3 to 3.8), diabetes mellitus (2.4; 95% CI 2.1 to 2.7), ischaemic heart disease (2.4; 95% CI 2.0 to 2.8), atrial fibrillation (1.9; 95% CI 1.5 to 2.3) and cerebrovascular disease (1.4; 95% CI 1.0 to 1.8). The cumulative incidence at 20 years of diabetes mellitus, chronic liver disease and chronic kidney disease was 12%, 11% and 11%, respectively. During follow-up, 495 patients (73%) died, with median survival of 5.7 years (95% CI 4.8 to 6.4). The overall SMR of patients with CP was significantly increased (2.3; 95% CI 2.1 to 2.6; p<0.0001) compared with the general population. Leading causes of death were malignancy (27%), infections (22%) and cardiovascular disease (6.9%).
conclusionCP is associated with increased risk of multiple comorbidities and elevated mortality as compared with the general population. Enhanced surveillance and early intervention strategies may help prevent or delay the onset of these associated conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.